Hamlet BioPharma AB publ (FRA:7ZT) Total Long-Term Assets: €2.19 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7ZT Hamlet BioPharma AB publ FRA:7ZT
31 GF Score
Price €0.58
! 2 Warning Signs
View Full Analysis

What is Hamlet BioPharma AB publ Total Long-Term Assets?

Hamlet BioPharma AB publ FRA:7ZT 31 Total Long-Term Assets is €2.19 Mil as of Mar. 2026. GuruFocus rates FRA:7ZT with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Hamlet BioPharma AB publ's Total Long-Term Assets for the quarter that ended in Mar. 2026 was €2.19 Mil.

Hamlet BioPharma AB publ Total Long-Term Assets Related Terms

Hamlet BioPharma AB publ Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Hamlet BioPharma AB publ's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hamlet BioPharma AB publ Total Long-Term Assets Chart

Hamlet BioPharma AB publ Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.81 3.66 2.80

Hamlet BioPharma AB publ Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.05 2.80 2.57 2.40 2.19
FRA:7ZT
31GF Score
Hamlet BioPharma AB publ FRA:7ZT
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hamlet BioPharma AB publ Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €2.19 Mil mean?
Hamlet BioPharma AB publ (FRA:7ZT) has a Total Long-Term Assets of €2.19 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Hamlet BioPharma AB publ and its competitors.
Is Hamlet BioPharma AB publ's Total Long-Term Assets too high?
Hamlet BioPharma AB publ's current Total Long-Term Assets is €2.19 Mil. Overall, Hamlet BioPharma AB publ has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hamlet BioPharma AB publ's Total Long-Term Assets compare to VRTX and REGN?
Hamlet BioPharma AB publ's Total Long-Term Assets of €2.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Hamlet BioPharma AB publ and its competitors. Hamlet BioPharma AB publ's current Total Long-Term Assets is €2.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hamlet BioPharma AB publ stock overvalued right now?
Hamlet BioPharma AB publ (FRA:7ZT) has a current Total Long-Term Assets of €2.19 Mil. The current Total Long-Term Assets is €2.19 Mil. Hamlet BioPharma AB publ's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Hamlet BioPharma AB publ (FRA:7ZT), the current Total Long-Term Assets is €2.19 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hamlet BioPharma AB publ Business Description

Other Exchanges HAMLET B:Sweden
Address Klinikgatan 32, BMC D10, Lund, SWE, SE-222 42
Hamlet BioPharma AB publ is a pharmaceutical company engaged in the research and development of drugs used for curing cancer.
31GF Score

Get the complete analysis for FRA:7ZT

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.58
Price